A mechanistic PK summary describes how sildenafil moves through the body as a sequence of input, distribution, biotransformation, and removal processes, without treating pharmacokinetics as a measure of clinical outcome. Absorption determines the rate and extent at which drug-related material enters systemic circulation, creating the initial input profile. Distribution then describes movement between the central circulation and peripheral spaces, shaping concentration relative to the amount present and the speed of compartmental equilibration. Metabolism transforms parent sildenafil through enzyme-mediated pathways, with CYP3A4 representing an important component of metabolic turnover. Elimination combines metabolic and other clearance processes to determine the decline of systemic concentrations over time. Together, these processes establish systemic input geometry, disposition geometry, and the resulting concentration-time profile. AUC represents integrated systemic exposure, while Cmax describes peak concentration magnitude and Tmax describes the time associated with that peak. Changes in any upstream or downstream determinant can alter one or more of these descriptors without requiring a change in every other PK feature. The mechanistic distinction between sildenafil as an active ingredient and Viagra as a branded formulation can also be framed through the same PK concepts; see viagra vs sildenafil.
Absorption forms the upstream portion of sildenafil PK geometry by determining how drug becomes available for entry into systemic circulation. Dissolution establishes the fraction of material that becomes available from the administered formulation environment, while gastric emptying influences when dissolved material reaches the principal intestinal absorption region. The absorption rate describes the temporal pattern of systemic input: a relatively rapid input process produces a steeper rising phase, whereas a more distributed input process spreads entry over a longer interval. Absorption extent describes how much of the available material ultimately contributes to systemic input, making it distinct from absorption rate. These dimensions can vary independently in mechanistic models. A change in rate can shift the shape and timing of the rising concentration phase without necessarily producing the same proportional change in total exposure. Likewise, a change in extent can alter the overall magnitude of systemic exposure while leaving the conceptual shape of the input process comparatively similar. The resulting concentration-time profile therefore reflects both how much enters and how quickly it enters. For a focused treatment of these upstream processes, see absorption.
Distribution describes how sildenafil moves after entering systemic circulation and how that movement shapes concentration-time geometry. A central compartment represents the rapidly accessible circulating space in a compartmental description, while peripheral compartments represent tissues or spaces reached through distributional transfer. Movement between these spaces changes the relationship between total drug amount and measured concentration. Distribution volume is therefore a concentration-to-amount descriptor rather than a literal anatomical volume occupied by the drug. Rapid transfer toward peripheral compartments can alter the early concentration profile and contribute to an initial distribution phase, while slower equilibration can sustain differences between central and peripheral concentrations before a later disposition phase becomes dominant. Redistribution represents the reverse movement from peripheral spaces toward the central compartment and can influence concentration behavior as systemic input falls. These processes are governed by transfer rates, partitioning characteristics, binding relationships, and compartmental connectivity in a PK model. Distribution is consequently distinct from elimination: redistribution changes where drug is represented within the modeled system, whereas clearance removes drug from the system. The mechanistic framework for these processes is described further in distribution.
Metabolism contributes to sildenafil PK by transforming parent drug into metabolites through enzyme-mediated biochemical pathways. CYP3A4 is a major metabolic pathway in the disposition of sildenafil, so its turnover contributes to the rate at which parent compound is converted and removed from the parent-drug pool. In a mechanistic representation, metabolic turnover can be expressed through intrinsic metabolic capacity, substrate availability, enzyme activity, and the relationship between hepatic extraction and systemic delivery to the metabolic site. Extraction describes the fraction of drug removed during passage through an eliminating organ and can be influenced by the balance between intrinsic clearance, protein binding, blood flow, and enzyme activity. Metabolism therefore connects concentration at the eliminating site with the rate of parent-drug disappearance and metabolite formation. Metabolites create a related but distinct disposition pathway, because formation depends on parent-drug turnover while subsequent concentrations depend on the metabolite's own distribution and elimination characteristics. The overall metabolic component is not equivalent to a single concentration-time parameter; instead, it is one determinant within the larger disposition system. The general process is covered in metabolism, while enzyme-specific geometry is addressed in cyp3a4.
Elimination describes the net removal of sildenafil-related material from systemic circulation and provides a major determinant of the descending concentration-time profile. Clearance is a proportionality concept linking the rate of irreversible removal to systemic concentration; it summarizes the capacity of eliminating pathways without itself representing a physical volume. Metabolic clearance can contribute substantially to total clearance, while other elimination pathways may contribute according to the disposition model. Following the peak and completion of the dominant absorption input, declining concentration reflects the balance between ongoing distribution, metabolic removal, and other clearance processes. The terminal phase is particularly informative about the slower disposition components that remain after faster distributional processes have diminished. Half-life is a derived descriptor of this decline rather than an independent elimination mechanism. In a simple one-compartment representation, half-life relates to clearance and apparent distribution volume, whereas multicompartment systems can contain multiple characteristic decline phases and corresponding apparent half-lives. Consequently, half-life should be interpreted as a descriptor of disposition geometry rather than as a complete description of every elimination process. The relationship between decline and this descriptor is explored in half-life.
Exposure geometry condenses different features of the sildenafil concentration-time profile into complementary PK descriptors. AUC, or area under the concentration-time curve, represents integrated systemic exposure over a defined time interval and therefore reflects the combined effects of systemic input and clearance. Cmax identifies the maximum observed or modeled plasma concentration and describes peak magnitude, making it sensitive to the interaction between absorption rate, absorption extent, distribution, and elimination. Tmax identifies the time associated with Cmax and therefore describes peak timing rather than peak size or total exposure. These parameters can change in different directions because they summarize different dimensions of the same concentration-time system. For example, a change in input rate can alter Tmax and Cmax while producing a less direct change in integrated exposure, whereas altered clearance can influence AUC and the descending portion of the curve. PK comparison therefore involves comparing the underlying exposure geometry rather than treating any single parameter as a complete disposition description. The broader comparison framework is covered by pk comparison, with focused treatment of peak magnitude in cmax and peak timing in tmax.
PK variability represents differences in the mechanistic parameters that generate sildenafil concentration-time profiles. Absorption variability can alter systemic input rate, input extent, rising-phase steepness, Cmax, and Tmax. Distribution variability can alter transfer between central and peripheral spaces, apparent distribution volume, equilibration rates, and the relationship between amount and concentration. Metabolic variability can modify parent-drug turnover and metabolite formation through changes in intrinsic metabolic capacity and pathway activity. Clearance variability can alter the rate of systemic removal, the descending concentration profile, integrated exposure, and terminal disposition geometry. These determinants can interact rather than operating as isolated switches. For example, a change in absorption can influence the concentration presented to distribution and metabolic pathways, while altered clearance can change the persistence of concentrations after systemic input has declined. Consequently, observed PK variability is a composite property of the input, distribution, metabolism, and elimination system. A mechanistic variability framework distinguishes parameter changes from clinical interpretation: it describes how concentration-time geometry can differ without assigning those differences an outcome-based meaning. The integrated framework is developed in pk variability.
Dissolution and gastric emptying form upstream determinants of sildenafil systemic input. Dissolution describes the transition of drug material into a form available for subsequent absorption, linking formulation-associated release processes with the amount accessible to the absorbing environment. Gastric emptying then influences the timing with which available material progresses from the stomach toward the intestinal region where substantial systemic uptake can occur. In a PK model, these processes are represented as determinants of the input function rather than as direct measures of concentration. Faster or slower emptying can redistribute the timing of available material, while differences in dissolution can alter the amount available for absorption at successive time points. The resulting input function is then filtered through absorption kinetics before appearing in systemic circulation. This means that the early concentration-time curve contains information about both upstream availability and downstream disposition, rather than reflecting absorption rate alone. Gastric emptying and dissolution therefore occupy different positions within the causal sequence, but both can contribute to the geometry of systemic entry. Their role in the broader input process is described in absorption.
Absorption rate and absorption extent describe complementary properties of systemic input. Absorption rate specifies how quickly available sildenafil enters systemic circulation, shaping the steepness and temporal spread of the rising concentration phase. A higher effective input rate tends to concentrate systemic entry into a narrower time region, whereas a slower input process distributes entry over a broader interval. Absorption extent describes the fraction of available drug that ultimately contributes to systemic circulation, connecting the amount available for uptake with systemic bioavailability. Rate and extent are therefore conceptually distinct: rate concerns timing, while extent concerns magnitude of input. A change in absorption rate can modify Cmax and Tmax through altered input geometry without necessarily producing a proportional change in total exposure. A change in absorption extent can alter systemic exposure magnitude while preserving a broadly similar temporal input pattern. Both parameters interact with distribution and clearance after entry, so their concentration-time effects cannot be interpreted independently of disposition. The relationship between systemic availability and input magnitude is further represented through bioavailability.
| Absorption Domain | Mechanistic Determinant | Link |
|---|---|---|
| Dissolution | Availability for absorption. | absorption |
| Gastric Emptying | Timing of systemic entry. | absorption |
| Absorption Rate | Rising-phase steepness. | absorption |
| Absorption Extent | Systemic input magnitude. | bioavailability |
After sildenafil reaches systemic circulation, distribution determines how drug amount is partitioned between the central compartment and peripheral spaces. Central-to-peripheral transfer is represented through rate constants or related intercompartmental parameters that describe movement away from the rapidly accessible circulating compartment. Peripheral-to-central transfer describes redistribution in the opposite direction. These flows influence measured plasma concentration because concentration depends on where drug resides within the modeled system, not simply on total amount present. During an early distribution phase, rapid transfer can produce a concentration decline even while total systemic drug amount has changed relatively little, because material is moving between compartments rather than being irreversibly eliminated. As distribution approaches equilibration, concentration differences between connected compartments become smaller and the observed profile increasingly reflects the slower disposition processes that remain. The resulting concentration-time curve is therefore a composite of input, distributional transfer, and elimination. Distribution should consequently be separated conceptually from clearance: transfer changes compartmental location, while clearance represents irreversible removal from the modeled system. The underlying compartmental framework is detailed in distribution.
Distribution volume provides a mechanistic relationship between the amount of sildenafil represented in the system and the corresponding concentration. It is an apparent parameter because it incorporates the extent to which drug distributes outside the measured central compartment rather than representing a literal anatomical space. A larger apparent distribution volume can correspond to a lower concentration for a given total amount, whereas a smaller value can correspond to a higher concentration for that same amount, depending on the model. Equilibration describes the approach toward a dynamic balance among connected compartments, with transfer rates determining how rapidly concentration differences diminish. Redistribution can subsequently return material from peripheral spaces toward the central compartment as systemic concentrations change. These processes shape both early and later portions of the concentration-time curve and can influence the relationship between Cmax, the post-peak decline, and terminal disposition. In multicompartment models, distribution and elimination can therefore generate multiple visible phases rather than a single exponential decline. The mechanistic interpretation of transfer, volume, and equilibration is developed in distribution.
| Distribution Domain | Mechanistic Determinant | Link |
|---|---|---|
| Transfer | Central ↔ peripheral movement. | distribution |
| Distribution Volume | Concentration–amount relationship. | distribution |
| Equilibration | Compartmental alignment. | distribution |
CYP3A4 turnover is an important component of sildenafil parent-drug metabolism. In mechanistic PK terms, enzyme-mediated turnover converts parent compound into metabolites and therefore contributes to the rate at which parent drug leaves the metabolically available pool. The magnitude of this contribution depends on factors such as intrinsic enzymatic activity, substrate concentration, enzyme availability, and the delivery of drug to the metabolic site. CYP3A4 activity can therefore be represented as part of intrinsic metabolic clearance rather than as a standalone concentration-time parameter. Hepatic delivery, protein binding, and extraction relationships determine how the intrinsic capacity of the pathway translates into observed systemic disposition. When metabolic turnover changes, the resulting effect propagates through the parent concentration-time profile because metabolism is coupled to the amount available for removal. Metabolite formation is correspondingly linked to parent-drug disappearance, although metabolite concentrations require their own distribution and elimination description. The key mechanistic point is that CYP3A4 represents a pathway within the larger metabolic network, connecting enzyme activity with parent-drug turnover. Its specific contribution to sildenafil disposition is covered in cyp3a4.
Extraction describes how effectively drug presented to an eliminating organ is removed during its passage through that organ. In hepatic disposition, extraction can be conceptualized through the interaction of blood flow, protein binding, and intrinsic metabolic capacity. Low-extraction behavior tends to make systemic removal more sensitive to intrinsic clearance and binding relationships, whereas higher-extraction behavior can place greater emphasis on delivery or flow constraints. These distinctions help separate enzyme capacity from the organ-level process through which drug is actually removed. Metabolite formation is the corresponding product-side process: parent sildenafil is transformed into metabolite species at rates determined by metabolic turnover, while the subsequent concentration of each metabolite depends on its own distribution and elimination. Thus, parent disappearance and metabolite appearance are mechanistically connected but are not interchangeable measurements. The combined metabolism geometry contributes to total clearance and therefore influences the concentration-time profile, AUC, and terminal decline. The complete framework treats metabolism as one component of disposition rather than equating it with every elimination process. The broader biochemical and PK relationships are described in metabolism.
| Metabolism Domain | Mechanistic Determinant | Link |
|---|---|---|
| CYP3A4 Turnover | Primary metabolic pathway. | cyp3a4 |
| Extraction | Intrinsic vs flow-limited. | metabolism |
| Metabolite Formation | Parent → metabolite geometry. | metabolism |
Clearance describes the volume of plasma or blood from which sildenafil is completely removed per unit time in an abstract PK sense. It is a composite descriptor of eliminating processes rather than a physical volume of drug removed. Metabolic clearance can arise from hepatic biotransformation, with the magnitude of systemic removal reflecting the interaction between intrinsic metabolic capacity, extraction, binding, and organ delivery. Total clearance then determines how rapidly systemic drug amount is reduced for a given concentration. Because clearance operates on the circulating drug pool, changes in clearance alter the descending portion of the concentration-time profile and can modify integrated exposure. Clearance also interacts with distribution volume when characteristic disposition rates are derived, meaning that the same clearance value can produce different decline behavior when paired with different distribution parameters. This relationship makes clearance a system-level determinant rather than an isolated measure of metabolic activity. In multicompartment models, separate distributional and elimination processes can contribute to distinct phases of decline, so a single clearance descriptor does not necessarily reproduce every visible feature of the curve. The relationship between clearance and terminal decline is summarized through half-life.
Terminal decline represents the later portion of the sildenafil concentration-time profile after faster input and distributional processes have diminished. In a simple one-compartment model, concentration declines approximately exponentially, and half-life provides the time associated with a 50% reduction under that model. In multicompartment systems, however, multiple exponential components can contribute to the observed curve, producing an early distribution phase followed by a slower terminal phase. Terminal half-life therefore functions as a descriptor of the dominant late-phase geometry rather than a complete representation of all drug movement or elimination. Mathematically, characteristic decline rates are related to clearance and apparent distribution parameters, so changes in either can alter the observed half-life. This is why half-life cannot be interpreted as an independent mechanism: it summarizes the combined behavior of underlying disposition processes. Terminal persistence in a concentration-time profile consequently depends on the interaction of distribution, metabolic turnover, and clearance. The focused relationship between these underlying determinants and the half-life descriptor is addressed in half-life.
AUC summarizes the integrated concentration-time profile over a specified interval and is therefore a measure of cumulative systemic exposure within that interval. Its magnitude is generated by the balance between systemic input and disposition. Input extent contributes to the amount entering circulation, while clearance determines how rapidly that amount is removed. Distribution can influence the shape of the concentration curve and therefore the time-resolved contribution to AUC, particularly when the measurement interval is finite. AUC should consequently be understood as an integrated descriptor rather than a direct measurement of absorption rate, peak concentration, or terminal half-life. Two concentration-time profiles can have similar integrated exposure while differing in peak magnitude and timing, because the same area can be distributed differently across time. Conversely, profiles with different AUC values can have similar Cmax values if their differences arise from later portions of the curve or from the duration of exposure above lower concentrations. AUC therefore captures one dimension of exposure geometry, while Cmax and Tmax describe other dimensions. The relationship among these descriptors and broader PK geometry is developed in pk comparison.
Cmax and Tmax describe the magnitude and timing of the peak within a sildenafil concentration-time profile. Cmax is the maximum observed or modeled concentration and therefore reflects the combined influence of systemic input rate, input extent, distribution, and disposition during the rising and peak portions of the curve. Tmax is the time at which Cmax occurs and is primarily a temporal descriptor of the balance between absorption input and the processes opposing concentration accumulation. A faster input process can shift the peak earlier and change its magnitude, while slower input can spread systemic entry over time and alter the rising-phase geometry. Distribution and elimination also influence the exact location and height of the peak because concentration at any moment reflects the net balance of drug entering and leaving the measured compartment. Cmax and Tmax should therefore be interpreted together with AUC rather than as substitutes for integrated exposure or total disposition. Cmax focuses on peak magnitude, whereas Tmax focuses on peak timing. Detailed treatment of peak concentration appears in cmax, while the timing descriptor is covered in tmax.
| Exposure Domain | Mechanistic Determinant | Link |
|---|---|---|
| AUC | Integrated exposure. | pk comparison |
| Cmax | Peak magnitude. | cmax |
| Tmax | Peak timing. | tmax |
Absorption variability changes the systemic input function that initiates sildenafil concentration-time behavior. Differences in dissolution, gastric emptying, intestinal availability, absorption rate, or absorption extent can alter when and how much drug enters systemic circulation. Rate variability primarily changes the temporal distribution of input, affecting the steepness and spread of the rising phase and potentially shifting Tmax or Cmax. Extent variability changes the magnitude of systemic input and can therefore influence integrated exposure. These dimensions are mechanistically separable: two input functions can have similar total input but different rates, or similar timing but different total amounts. Once drug enters circulation, the resulting concentration profile is further modified by distribution and clearance, so an observed difference in Cmax or Tmax cannot automatically be assigned to absorption alone. Input geometry is therefore the first stage in a sequence of interacting PK determinants. A complete mechanistic description tracks the relationship between upstream availability and the downstream disposition processes that transform the input function into an observed concentration-time curve. Absorption-related variability is part of the broader framework described in pk variability.
Distribution variability reflects differences in the modeled transfer of sildenafil between central and peripheral compartments and in the apparent relationship between amount and concentration. Changes in distribution volume can alter concentration for a given amount, while changes in intercompartmental transfer rates can modify the speed and magnitude of early redistribution and equilibration. These changes can affect the shape of the concentration-time curve without necessarily representing differences in the total amount of drug introduced into the system. Distribution variability can therefore influence peak concentration, early decline, and the transition between distribution and terminal disposition phases. Because distribution and elimination operate simultaneously, a change in one process can modify the apparent contribution of another when concentration data are interpreted through a compartmental model. The mechanistic distinction remains that distribution relocates drug between connected spaces, whereas elimination removes drug from the system. Variability in these processes consequently contributes to differences in disposition geometry even when systemic input is unchanged. The broader treatment of these parameter differences is included in pk variability.
Metabolism and clearance variability alter the downstream portion of sildenafil disposition by changing the rate at which parent drug is transformed or otherwise removed. Differences in CYP3A4-mediated turnover can modify intrinsic metabolic clearance and therefore change the parent-drug disappearance rate. Variability in extraction relationships can alter how intrinsic metabolic capacity translates into organ-level removal, while variability in total clearance changes the relationship between systemic concentration and removal rate. These effects can propagate into AUC, the descending concentration-time profile, and terminal disposition geometry. Metabolic turnover and total clearance are related but not identical concepts: metabolism describes biochemical transformation, whereas clearance summarizes the net removal capacity of the system. Distribution parameters can also interact with clearance to determine characteristic decline rates, so a change in terminal behavior does not necessarily identify a single altered mechanism. PK variability is therefore best represented as a network of parameter differences spanning input, transfer, transformation, and removal. The integrated mechanistic treatment of these sources is provided in pk variability.
| Variability Domain | Mechanistic Determinant | Link |
|---|---|---|
| Absorption Variability | Input geometry variability. | pk variability |
| Distribution Variability | Transfer & volume variability. | pk variability |
| Metabolism Variability | Turnover & extraction. | pk variability |
| Clearance Variability | Elimination variability. | pk variability |
A mechanistic PK summary describes the chain of processes that determines sildenafil concentration over time. It begins with systemic input, which depends on how rapidly and extensively drug becomes available for absorption and enters circulation. Distribution then describes movement between the central compartment and peripheral spaces, influencing the relationship between drug amount and measured concentration. Metabolism describes biochemical transformation of parent drug, including enzyme-mediated turnover, while elimination describes the net removal of drug from the systemic compartment. These processes together generate concentration-time geometry. AUC summarizes integrated exposure over a defined interval, Cmax summarizes peak concentration magnitude, and Tmax summarizes peak timing. None of these descriptors alone represents the complete PK system. A mechanistic summary therefore focuses on relationships among input, transfer, transformation, clearance, and resulting exposure rather than assigning clinical meaning to a concentration profile. The emphasis is on explaining how changes in underlying PK parameters propagate through the concentration-time curve.
Absorption differences modify the systemic input function that feeds the disposition system. Absorption rate determines how quickly drug enters circulation and therefore influences the temporal shape of the rising concentration phase. A more concentrated input process can produce a steeper rise and earlier peak formation, whereas a more distributed input process can spread the rising phase across a longer interval. Absorption extent determines the amount that ultimately contributes to systemic input and therefore affects the magnitude of exposure entering the systemic compartment. Rate and extent are distinct parameters, so changes in one do not necessarily imply proportional changes in the other. The resulting concentration profile is also shaped by distribution and clearance, meaning that absorption cannot be interpreted independently from downstream disposition. Consequently, Cmax, Tmax, and AUC can respond differently to changes in absorption geometry. A mechanistic analysis treats these parameters as outputs of the complete input-disposition system rather than as direct one-to-one measures of absorption.
Distribution processes determine how sildenafil moves between the central circulation and peripheral compartments after systemic entry. This movement changes the relationship between total drug amount and concentration measured in the central compartment. Rapid distribution can produce an early concentration decline as drug moves away from the central space, even when irreversible elimination has not produced a corresponding reduction in total systemic amount. Slower transfer can prolong the equilibration process and maintain concentration differences between connected compartments. Distribution volume provides an apparent relationship between amount and concentration, while intercompartmental transfer rates describe the speed of movement between modeled spaces. Redistribution can subsequently move material back toward the central compartment as concentration gradients change. These processes contribute to the shape of the concentration-time profile and can create distinct distribution and terminal phases. Distribution is therefore mechanistically different from clearance: distribution relocates drug within the system, while clearance removes it. The observed PK curve reflects both processes operating alongside systemic input and metabolic turnover.
Metabolism contributes to PK variability by altering the rate at which sildenafil is transformed from parent compound into metabolites. Enzyme-mediated turnover, including CYP3A4 activity, forms part of intrinsic metabolic clearance. Differences in intrinsic capacity can therefore change the rate at which parent drug becomes available for removal through metabolic pathways. The observed effect also depends on extraction, hepatic delivery, protein binding, and the relationship between intrinsic metabolic capacity and organ-level clearance. Increased or decreased metabolic turnover can consequently change the parent concentration-time profile and the amount of systemic exposure remaining at successive time points. Metabolite formation is coupled to parent-drug disappearance, but metabolite concentrations follow their own distribution and elimination processes. Metabolic variability is therefore not identical to variability in total clearance, although the two are connected. In a complete PK model, metabolism interacts with absorption, distribution, and elimination so that changes in one determinant can propagate through several exposure descriptors. AUC, Cmax, Tmax, and terminal decline can consequently reflect combined effects rather than a single metabolic parameter.
Elimination processes determine how rapidly sildenafil-related material is removed from the systemic compartment after and during systemic input. Clearance provides a quantitative descriptor of the net capacity for irreversible removal, incorporating the contributions of relevant eliminating pathways. Metabolic clearance can be an important component, with enzyme-mediated transformation contributing to parent-drug disappearance. The concentration-time profile after the peak reflects the balance between remaining input, distributional transfer, redistribution, and ongoing clearance. Once input has diminished, clearance becomes increasingly important to the descending concentration profile. In multicompartment systems, the terminal phase may reflect the interaction between clearance and slower distributional processes rather than a single isolated removal mechanism. Half-life summarizes a characteristic decline rate but does not itself constitute an elimination pathway. Its value depends on underlying disposition parameters, including clearance and apparent distribution behavior. Exposure persistence is therefore an emergent property of the complete disposition geometry. A slower characteristic decline can arise from different combinations of clearance and distribution parameters, which is why terminal half-life should be interpreted as a descriptor of the resulting PK profile rather than as a standalone mechanism.
AUC, Cmax, and Tmax summarize different dimensions of the sildenafil concentration-time profile. AUC represents integrated exposure over a defined time interval, capturing the accumulated concentration signal across that interval. Cmax represents the maximum concentration and therefore describes peak magnitude. Tmax represents the time at which that peak occurs and therefore describes peak timing. Because these descriptors measure different features, they can change independently. A change in absorption rate may shift Tmax and modify Cmax while having a different effect on AUC. A change in absorption extent can alter integrated exposure and peak magnitude, while changes in clearance can alter AUC and the descending portion of the curve. Distribution can further modify the relationship between amount and concentration and influence the shape around the peak and later phases. Consequently, no single parameter fully describes PK geometry. Together, AUC, Cmax, and Tmax provide complementary summaries of exposure magnitude, peak magnitude, and peak timing, while the underlying mechanisms remain the combined effects of systemic input, distribution, metabolism, and elimination.